Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results
· Closing of the €115 million licensing transaction with SERB
· Cash and cash equivalents amounted to 1,337.2 MSEK as of 30 September 2026
· The first commercial patient in Australia received a living-donor kidney transplant following treatment with Idefirix (Imlifidase)
· Cash and cash equivalents amounted to 1,337.2 MSEK as of 30 September 2026
· The first commercial patient in Australia received a living-donor kidney transplant following treatment with Idefirix (Imlifidase)
Lund, Sweden, November 11, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its interim report for the three and nine months ended September 30, 2026.
